Credent Connect IPO is a book-built issue of ₹93.90 crores, comprising an entirely fresh issue of 0.50 crore shares aggregating to ₹93.90 crore. The IPO will open for subscription on Aug 13, 2026 and close on Aug 17, 2026. The allotment is expected to be finalized on Aug 18, 2026, with the shares proposed to be listed on the NSE SME platform on Aug 20, 2026.
The issue has a price band of ₹179 to ₹189 per share, with a lot size of 600 shares. The minimum retail investment is ₹2,26,800 (1,200 shares), based on the upper price band. For HNI investors, the minimum application is 3 lots (1,800 shares), requiring an investment of ₹3,40,200. Hem Securities Ltd. is the book running lead manager, while Kfin Technologies Ltd. is the registrar to the issue.
For detailed information on the company’s business, financials, risk factors, and the proposed utilisation of proceeds, investors should refer to the Credent Connect IPO Red Herring Prospectus (RHP) before making an investment decision.
Company Overview
Incorporated in June 2015 as Credent Cold Chain Logistics Private Limited, Credent Connect N Care Limited is an integrated healthcare services and logistics company providing technology-driven operational, workforce and supply chain solutions to healthcare institutions across India. The company follows a B2B model and serves diagnostic laboratories, IVD companies, pharmaceutical companies, hospitals, clinics and other healthcare businesses.
Its service portfolio covers home sample collection through trained phlebotomists, laboratory and healthcare manpower solutions, diagnostic and paramedical services, healthcare logistics, operations and supply chain management, corporate wellness programs, and technology-enabled courier aggregation through its C3 Post platform. The company also provides temperature-controlled and time-sensitive transportation for diagnostic samples, medical supplies, reagents and other healthcare consignments.
Credent Connect N Care has a pan-India presence supported by warehouses, branch offices, commercial vehicles, field personnel and technology systems for tracking, workforce management and operational coordination. Its corporate wellness business operates under the “C3 Wellness” brand and provides health camps, vaccination programs, preventive health check-ups, radiology and diagnostic services, and on-ground healthcare manpower.
As of March 31, 2026, the company had a workforce of 6,338 employees, including 4,052 payroll and 2,286 contractual employees. The company has strengthened its operations through acquisitions of Credent Healthcare Private Limited, Credent Team Private Limited and Alltrak Technologies Private Limited. Its capabilities are supported by ISO 9001:2015 and ISO 15189:2022 certifications, along with an experienced promoter-led management team with expertise in healthcare logistics and operations.
IPO Details
| Particulars | Details |
|---|---|
| IPO Date | 13 to 17 Aug, 2026 |
| Allotment | Tue, Aug 18, 2026 |
| Listing Date | Thu, Aug 20, 2026 |
| Face Value | ₹10 per share |
| Price Band | ₹179 to ₹189 per share |
| Lot Size | 600 Shares |
| Issue Type | Book Building IPO |
| Sale Type | Fresh capital only |
| Total Issue Size | 49,68,000 shares (agg. up to ₹94 Cr) |
| Reserved for Market Maker | 2,52,000 shares (agg. up to ₹5 Cr) |
| Fresh Issue (Ex Market Maker) | 47,16,000 shares (agg. up to ₹89 Cr) |
| Shareholding Pre-Issue | 1,32,54,900 shares |
| Shareholding Post-Issue | 1,82,22,900 shares |
| Listing Exchange | NSE SME |
(Compiled from RHP and market updates)
Industry Context
- India’s diagnostic laboratory market grew from USD 11.07 billion in FY 2021 to USD 16.50 billion in FY 2025, registering a CAGR of 10.5%, driven by preventive healthcare, lifestyle diseases and wider access in Tier-2 and Tier-3 cities.
- Major players such as Dr. Lal PathLabs, Metropolis Healthcare, Thyrocare Technologies and others are expanding through central labs, collection centres and technology-enabled networks, improving accessibility and service efficiency.
- Home sample collection, digital bookings, LIS, automation, AI-enabled testing, molecular diagnostics and genomics are increasingly improving convenience, testing capacity and operational efficiency.
- The diagnostic laboratory market is expected to increase from USD 16.50 billion in FY 2025E to USD 31.50 billion by FY 2030E, with growth supported by preventive care, chronic disease screening and advanced testing.
- Pharmaceutical logistics requires controlled handling of sensitive products. Cold rooms operate at 2−8°C, deep freezers at −20°C or below, and controlled ambient zones at 15−25°C, supported by monitoring and validated storage systems.
Business Strengths
- Credent Connect provides multiple healthcare-related services under one platform, including healthcare logistics, diagnostic support, manpower solutions, sample collection and operational assistance. This integrated model enables healthcare institutions to access several complementary services through a single service provider.
- The company has established a broad presence across India and caters to a wide range of B2B customers, including diagnostic laboratories, IVD companies, pharmaceutical businesses, hospitals, clinics and other healthcare enterprises. Its distributed operations support service delivery across multiple locations.
- Credent Connect manages the movement of diagnostic samples, medical supplies, reagents and other healthcare consignments. Its logistics capabilities include temperature-controlled transportation and time-sensitive deliveries, which are particularly important for healthcare products and diagnostic materials requiring controlled handling.
- The company uses technology to improve operational coordination, workforce management, tracking and service execution. Platforms such as C3 Post and C3 HRMS support activities including courier aggregation, employee management and real-time operational monitoring.
- Beyond logistics, the company operates across diagnostic services, healthcare manpower, home sample collection, paramedical support and corporate wellness. This diversified offering allows it to address different operational requirements of healthcare institutions and reduces reliance on a single service category.
- The company has expanded its capabilities through acquisitions such as Credent Healthcare Private Limited, Credent Team Private Limited and Alltrak Technologies Private Limited. These acquisitions have helped broaden its service capabilities and strengthen its presence across healthcare operations and logistics.
Business Risks
- The company’s business is closely linked to the performance and spending patterns of the healthcare industry. Any slowdown in diagnostic, pharmaceutical or hospital activity could affect demand for its services.
- The transportation of diagnostic samples, medical supplies and temperature-sensitive consignments requires strict handling and monitoring. Any breakdown in cold-chain infrastructure, delays or improper handling could result in losses, damaged consignments and reputational concerns.
- Several of the company’s services rely on trained phlebotomists, healthcare professionals, logistics personnel and other field employees. Difficulty in recruiting, training or retaining suitable personnel could affect its ability to maintain service standards.
- The company relies on technology platforms for workforce management, tracking, courier aggregation and operational coordination. System failures, data breaches, cyberattacks or technology disruptions could interrupt operations and compromise sensitive information.
- Credent Connect operates in multiple segments where it faces competition from established healthcare service providers, diagnostic companies, logistics operators and specialised manpower agencies. Competitive pricing or stronger service offerings from rivals could put pressure on margins and market share.
- The company has expanded through acquisitions, which can involve challenges related to integrating employees, systems, processes and operations. Failure to achieve expected synergies from these acquisitions could affect business performance.
Financial Performance
Credent Connect N Care Limited- Financials (₹ in lakh)
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue from Operations | 21,416.18 | 7,794.26 | 7,573.32 |
| Net Worth | 4,379.07 | 1,590.27 | 1,365.60 |
| EBITDA | 2,846.36 | 499.48 | 429.63 |
| EBITDA Margin (%) | 13.29% | 6.41% | 5.67% |
| Profit After Tax (PAT) | 1,844.78 | 224.67 | 266.44 |
| Return on Capital Employed (%) | 61.81% | 16.96% | 20.00% |
| Return on Equity (%) | 40.00% | 15.20% | 21.62% |
(Source: RHP)
Key Ratios & Metrics
| KPI | Mar 31, 2026 | Mar 31, 2025 |
|---|---|---|
| Return on Equity (ROE) | 40.00% | 15.20% |
| Return on Capital Employed (ROCE) | 61.81% | 16.96% |
| Debt-to-Equity Ratio | 0.50 | 0.47 |
| Return on Net Worth (RoNW) | 42.13% | 14.13% |
| PAT Margin | 8.61% | 2.88% |
| EBITDA Margin | 13.29% | 6.41% |
| Net Asset Value (NAV per share) | ₹33.12 | ₹15.59 |
(Source: RHP)
Objects of the Offer
- Working capital support for Credent Healthcare Private Limited, the Company’s wholly owned subsidiary.
- Capital expenditure of Credent Healthcare Private Limited, including the purchase of machinery.
- Meeting the Company’s working capital requirements to support its ongoing business operations.
- Repayment or partial repayment of existing borrowings availed by the Company.
- General corporate purposes, including other permitted business and operational requirements.
Conclusion
Credent Connect N Care Limited operates across the growing healthcare services and logistics ecosystem, offering an integrated mix of logistics, diagnostic support, workforce solutions and corporate wellness services. Its pan-India presence, diversified service portfolio, technology-enabled operations and strategic acquisitions provide a foundation for future growth. However, investors should also consider risks related to operational complexity, workforce dependence, competition, regulatory requirements, technology disruptions and the need to maintain consistent service quality.
Overall, investors should evaluate the company’s business model, financial performance, industry outlook, competitive positioning, valuation, and risk factors in detail, and carefully review the Red Herring Prospectus (RHP) before making an informed investment decision.
Disclaimer: Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. This content is purely for informational purposes only and should not be considered as investment advice or a recommendation. Securities quoted are for illustration purposes only and not recommendatory. Investors are requested to do their own due diligence before investing.
Paytm Money Ltd. SEBI Reg. No. Broking – INZ000240532; Depository Participant – IN – DP – 416 – 2019, Depository Participant Number: CDSL – 12088800. Trading and clearing member of NSE (90165, M52073), BSE (6707), MCX (57525), NCDEX (1315, M51110), and MSEI (85300). SEBI Reg. No. Research Analyst – INH000020086. Regd. Office: 136, 1st Floor, Devika Tower, Nehru Place, Delhi – 110019. For complete Terms & Conditions and Disclaimers visit: https://www.paytmmoney.com/stocks/policies/terms
